Age Dependent Abnormalities of Serum AST Levels Children Hospitalized with COVID-19
Niculae Ion Nedelcu1, Magdalena George2 and David H Van Thiel2*
1Infectious and Tropical Diseases Hospital "Dr Victor Babes", Bucharest, Romania
2Advanced Liver and Gastrointestinal Disease Center, Berwyn, IL, USA
*Corresponding Author: David H Van Thiel, Advanced Liver and Gastrointestinal Disease Center, Berwyn, IL, USA.
January 03, 2022; Published: September 27, 2022
AST levels have been reported to he increased concern children and adults with COVID-19 infection. The majority of these cases with an increased AST level have clinically advanced COVID-19 disease. A wide range of possible mechanisms responsible for the increased.
AST level have been advanced, but no single factor been identified as being responsible. Laboratory evidence for either a subclinical coagulopathy in children or an overt coagulopathy in adults is frequently present in individuals with increased AST level, who are infected with COVID-19. Most likely, a combination of factors contributing to the increased AST levels and COVID-19 infected adults. In contrast, no single or combination of factors has been identified as being responsible for the increased AST levels in children. It has been proposed by several groups in Asia that t" l,! immaturity of the neonatal liver I’ll be responsible, but no specific factor of the immature liver has been proposed or identified.
Recognizing that the problems of an abnormal AST children is highest in those less than age 2 and declines progressively thereafter such that rare cases of AST elevations are identified in children age more than 2 and declines through age 5 years. Recognizing this age-dependent prevalence of an elevated AST in children infected with COVID-19, it is proposed to be the failure to develop Lepetic plates with endothelial cell linings resulting in the creation of a subendothelial space variant mononuclear cells consisting of macrophages, functional B cells that selectively secrete IgA as well as a wide array of cytokines that in combination with T cells that protect the liver from viral induced liver cell injury.
Keywords: COVID-19; Serum; Children
- Patel A., et al. “New onset anosmia and ageusia in adult patents diagnosed with SARS-CoV-2 Infection”. Clinical Microbiology and Infection 9 (2020): 1236-1241.
- Guan W-J., et al. “Clinical characteristics of coronavirus disease 2019 in China”. The New England Journal of Medicine 328 (2020): 1708-1720.
- Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395 (2020): 49T-506.
- Nisha S., et al. “SARS-CoV-2 (COVID-19): What do we know about children? A systematic review”. Clinical Infectious Diseases9 (2020): 2469-2479.
- Kawamura Y., et al. “Immune response against SARS-CoV-2 in pediatric patients including young infants”. Journal of Medical Virology 3 (2021): 1776-1779.
- Dean AG., et al. “Epi I IfoTM, a database and statistics program for public health professionals”. CDC, Atlanta, GA, USA, (2011).
- Luglio M., et al. “COVID-19 and Liver Damage: Narrative Review and Proposed Clinical Protocol for Critically ill Pediatric Patients”. Clinics (Sao Paulo) 75 (2020): 0250.
- Zimmerman I-IJ. “Drug-induced liver disease”. In Diseases of the Liver, 8th; In: SciffER, Sorrel MF, Maddrey WC, editors. Schiff's Lippincott-Raven Publishers. Philadelphia, PA, USA (1999): 973-1064.
- Boregowda U., et al. “Serum Activity of Liver Enzymes Is Associated With Higher Mortality in COVID-19: Systematic Review and Meta-Analysis”. Frontiers in Medicine (Lausanne) (2020).
- S Scalia. “Simultaneous determination of free and conjugated bile acids in human gastric juice by high-performance liquid chromatography”. Journal of Chromatography2 (1988): 259-269.
- Chen L Y., et al. “Liver damage At admission is an independent prognostic factor for COVID-19”. Journal of Digestive Diseases 9 (2020): 512-518.
- Wu Y., et al. “Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta analysis”. Hepatology International5 (2020): 621-637.
- Cai Q., et al. “COVID-19: Abnormal liver function tests”. Journal of Hepatology3 (2020): 566-574.
- Kumar-M P., et al. “Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis”. Hepatology International5 (2020): 711-722.
- Ramachandran P., et al. “Increased Serum Aminotransferase Activity and Clinical Outcomes in Coronavirus Disease 2019”. Journal of Clinical and Experimental Hepatology6 (2020): 533-539.
- Ma X., et al. “The clinical characteristics of pediatric inpatients with SARS-CoV-2 infection: A meta-analysis and systematic review”. Journal of Medical Virology1 (2021): 234-240.
- Wu H., et al. “Clinical and immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China”. JAMA 3.6 (2020): e2010895.
- Yong - Hai Zhou., et al. “Abnormal liver enzymes in children and infants with COVID - 19: A narrative review of case - series studies”. Pediatric Obesity12 (2020).
- Miao H., et al. “Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in Children”. European Journal of Clinical Microbiology and Infectious Diseases 39 (2020): 2211-2223.